menu
    • menu
    [{"orgOrder":0,"company":"Apimeds Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Undisclosed","year":"2010","type":"Inapplicable","leadProduct":"Apitox","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Apimeds Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apimeds Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Apimeds Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Apimeds Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Protein","year":"2018","type":"Inapplicable","leadProduct":"Honeybee Toxin","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Apimeds Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Apimeds Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Apimeds Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Apimeds Pharmaceuticals","sponsor":"D. Boral Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Honeybee Toxin","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Apimeds Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Apimeds Pharmaceuticals \/ D. Boral Capital","highestDevelopmentStatusID":"10","companyTruncated":"Apimeds Pharmaceuticals \/ D. Boral Capital"},{"orgOrder":0,"company":"Apimeds Pharmaceuticals","sponsor":"D. Boral Capital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Honeybee Toxin","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Apimeds Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Apimeds Pharmaceuticals \/ D. Boral Capital","highestDevelopmentStatusID":"10","companyTruncated":"Apimeds Pharmaceuticals \/ D. Boral Capital"}]

    Find Clinical Drug Pipeline Developments & Deals by Apimeds Pharmaceuticals

    Menu

    Apimeds Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Apimeds Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Apimeds Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Honeybee Toxin

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : D. Boral Capital

                            Deal Size : $13.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Apimeds Pharmaceuticals US, Inc. Announces Closing of Initial Public Offering

                            Details : The net proceeds from the offering will be used to fund the clinical development of Apitoxin, which is being evaluated for the treatment of Knee Osteoarthritis.

                            Product Name : Apitoxin

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            May 12, 2025

                            Lead Product(s) : Honeybee Toxin

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : D. Boral Capital

                            Deal Size : $13.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Apimeds Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Apimeds Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Honeybee Toxin

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : D. Boral Capital

                            Deal Size : $13.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Apimeds Pharmaceuticals US, Inc. Announces Pricing of Initial Public Offering

                            Details : The net proceeds from the offering will be used to fund the clinical development of Apitoxin, which is being evaluated for the treatment of Knee Osteoarthritis.

                            Product Name : Apitoxin

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            May 08, 2025

                            Lead Product(s) : Honeybee Toxin

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : D. Boral Capital

                            Deal Size : $13.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Apimeds Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Apimeds Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Honeybee Toxin

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluate Safety and Efficacy of Apitox Add-on Therapy for Improving Disability and Quality of Life in MS Patie...

                            Details : Apitox (Honeybee Toxin) is a Other Large Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Multiple Sclerosis.

                            Product Name : Apitox

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            October 18, 2018

                            Lead Product(s) : Honeybee Toxin

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Apimeds Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Apimeds Pharmaceuticals

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apitox

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Apitox, Honeybee Toxin for Pain and Inflammation of Osteoarthritis

                            Details : Apitox is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Osteoarthritis, Knee.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 28, 2010

                            Lead Product(s) : Apitox

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth